Seasoned investor with 20 years of experience and a strong track record strengthens VC’s leadership in early-stage life science investments PARIS, France – September 10, 2024 — Sofinnova Partners (“Sofinnova”), a leading European venture capital firm in life sciences, based in Paris, London, and Milan, announced the appointment of Karl Naegler as Partner. This strategic hire also […]
Financing led by Novo Holdings, including new investment from EQT Life Sciences – LSP Dementia Fund, OrbiMed and SR One with participation from existing investors M Ventures, Sofinnova Partners, GSK Equities Investments Limited and Johnson & Johnson Innovation – JJDC, Inc. Funds will be used to progress lead asset ASN51, an oral small molecule OGA […]
Additional funding will be used to explore novel biology around the MMR pathway and accelerate progression of the lead program into candidate selection London, UK, 22 May 2024 – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that Bristol Myers Squibb (NYSE: BMY) has joined its oversubscribed Series B extension round. The additional investment […]
Media release Basel, Switzerland, 22.05.2024 BaseLaunch announces a new partnership with AbbVie Further strengthens BaseLaunch’s global pharma industry partnerships 24 early-stage biotech ventures have now been supported by BaseLaunch Portfolio companies have raised over US$ 600 million in equity capital BaseLaunch, the Basel-based biotech venture incubator, today announces that AbbVie has become its newest partner. […]
Novo Holdings A/S (“Novo Holdings”) today announced that it has agreed to acquire a majority stake in Single Use Support, a fast-growing life science tools company providing advanced technology solutions for the pharmaceutical production process. Novo Holdings will acquire an approximately 60% controlling stake, alongside the two company founders who will each retain 10% and […]
